NASDAQ:KLRA Kailera Therapeutics (KLRA) Stock Price, News & Analysis $12.20 -0.37 (-2.94%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kailera Therapeutics Stock (NASDAQ:KLRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kailera Therapeutics alerts:Sign Up Key Stats Today's Range$11.86▼$12.6850-Day Range$10.00▼$14.9152-Week Range$9.76▼$28.23Volume510,056 shsAverage Volume933,228 shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice Target$43.00Consensus RatingModerate Buy Company Overview Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals. The company is based in Watertown, Massachusetts, and is led by President and Chief Executive Officer Ron Renaud.AI Generated. May Contain Errors. Read More Kailera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreKLRA MarketRank™: 2.29009152407 of 5 starsKailera Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 460th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingKailera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKailera Therapeutics has a consensus price target of $43.00, representing about 252.5% upside from its current price of $12.20.Amount of Analyst CoverageKailera Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Kailera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kailera Therapeutics are expected to decrease in the coming year, from ($3.71) to ($3.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKailera Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.30% of the float of Kailera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKailera Therapeutics has a short interest ratio ("days to cover") of 7.85.Change versus previous monthShort interest in Kailera Therapeutics has recently decreased by 1.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKailera Therapeutics does not currently pay a dividend.Dividend GrowthKailera Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentKailera Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kailera Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KLRA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Kailera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kailera Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsKailera Therapeutics has minimal institutional ownership at this time.Read more about Kailera Therapeutics' insider trading history. Receive KLRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kailera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRA Stock News HeadlinesCanaccord Genuity Group Begins Coverage on Kailera Therapeutics (NASDAQ:KLRA)November 11, 2026 | americanbankingnews.comKailera Therapeutics to Present at ObesityWeek 2026November 10, 2026 | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 17 at 1:00 AM | Porter & Company (Ad)Kailera Therapeutics: Phase 3 obesity launch set for 2027November 5, 2026 | 247wallst.comKailera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMKailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNovember 4, 2026 | globenewswire.comKailera Therapeutics to Participate in November Investor ConferencesNovember 3, 2026 | globenewswire.comKailera Therapeutics (KLRA) Stock Forecast & Price TargetOctober 11, 2026 | investing.comSee More Headlines KLRA Stock Analysis - Frequently Asked Questions How have KLRA shares performed this year? Kailera Therapeutics' stock was trading at $26.00 on April 17, 2026. Since then, KLRA stock has decreased by 53.1% and is now trading at $12.20. How were Kailera Therapeutics' earnings last quarter? Kailera Therapeutics, Inc. (NASDAQ:KLRA) announced its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.81. When did Kailera Therapeutics IPO? Kailera Therapeutics (KLRA) raised $586 million in an initial public offering on Friday, April 17th 2026. The company issued 39,062,500 shares at $14.00-$16.00 per share. When did Kailera Therapeutics' lock-up period expire? Kailera Therapeutics's lock-up period expired on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its initial public offering on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. Since the end of Kailera Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Kailera Therapeutics' major shareholders? Kailera Therapeutics' top institutional shareholders include State Street Corp (1.73%), Marshall Wace LLP (0.68%), Goldman Sachs Group Inc. (0.54%) and Aberdeen Group plc (0.33%). Insiders that own company stock include Andrew T Kaplan, Adam Koppel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Kailera Therapeutics? Shares of KLRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2026Today11/17/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KLRA CIK2096997 Webwww.kailera.com Phone(508) 440-9475FaxN/AEmployees145Year Founded2024Price Target and Rating Average Price Target for Kailera Therapeutics$43.00 High Price Target$57.00 Low Price Target$30.00 Potential Upside/Downside+252.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3,651.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.35% Return on Assets-38.58% Debt Debt-to-Equity RatioN/A Current Ratio21.84 Quick Ratio21.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.94 per share Price / Book1.54Miscellaneous Outstanding Shares129,850,000Free FloatN/AMarket Cap$1.58 billion OptionableOptionable BetaN/A Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:KLRA) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kailera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kailera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.